Cystic fibrosis gene therapy

Drug Profile

Cystic fibrosis gene therapy

Alternative Names: Compacted DNA; DNA nanoparticle gene therapy; Plasmid DNA vector expressing cystic fibrosis transmembrane gene

Latest Information Update: 19 Sep 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Copernicus Therapeutics
  • Class Gene therapies
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cystic fibrosis

Most Recent Events

  • 19 Sep 2011 No development reported - Phase-I/II for Cystic fibrosis in USA (Intranasal)
  • 19 Sep 2011 No development reported - Preclinical for Cystic fibrosis in USA (Intrapulmonary)
  • 25 Mar 2008 Clinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top